Upper limb lesions
Conditions
Interventions
Experimental group1:0.33% ropivacaine + butorphanol (10ug / kg)
Experimental group2:0.33% ropivacaine + butorphanol (20ug / kg)
Experimental group3:0.33% ropivacaine + butorphanol (30ug / kg)
Experimental group4:0.33% ropivacaine + butorphanol (40ug / kg)
Control group:0.33% ropivacaine
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 60 years; 2. ASA classification: I-II patients; 3. Patients undergoing upper extremity surgery with elective nerve block anesthesia; 4. Voluntarily participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to butofino or ropivacaine; 2. Patients with abnormal preoperative coagulation function; 3. The skin at the puncture site is infected or damaged; 4. 18kg/m230kg/m2; 5. Patients with bradycardia, atrioventricular block, and cardiac insufficiency; 6. Serious damage to liver and kidney function; 7. Those with a history of chronic pain.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Onset time of sensory block;Onset time of motor block;Complete sensory block time;Complete motor block time;Duration of sensory block;Duration of motor block; | — |
Secondary
| Measure | Time frame |
|---|---|
| visual pain score;Mean arterial pressure ;Ramsay Score;Anesthesia satisfaction and score of patients; | — |
Countries
China
Contacts
Public ContactWang Fangjun
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed